Project
A phase 3 multicenter, randomized, prospective, open-label trial of ibrutinibmonotherapy versus fixed-duration venetoclax plus obinutuzumab versusfixed-duration ibrutinib plus venetoclax in patients with previously untreatedchronic lymphocytic leukemia (CLL)
Ongoing - recruitment closed · 2021 until 2099
Baumann Michael, Harder Anja, Quinter Janine
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Ongoing - recruitment closed
Start Date
2021
End Date
2099
Financing
SAKK
Labels
leukemia